热门资讯> 正文
罗氏将以35亿美元收购89 bio，利用GF 21模拟物增强心血管、肾脏和代谢疾病的渠道
2025-09-18 14:42
- 89bio's pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most prevalent comorbidities of obesity
- Acquisition supports Roche's strategy as it enhances the company's portfolio in cardiovascular, renal, and metabolic diseases (CVRM) and offers optionality for future combination development
- Roche to acquire 89bio for US$14.50 per share in cash at closing, representing a total equity value of approximately US$2.4 billion. Stockholders would also receive a non-tradeable contingent value right (CVR) for up to an aggregate of US$6.00 per share in cash, representing a total deal value of up to approximately US$3.5 billion
推荐文章
港股周报丨降息周期重启！美联储如期降息25个基点；港股通年内净流入突破1万亿港元
美股机会日报 | 5.3万亿美元期权到期！美股“三巫日”今夜来袭；联邦快递盘前一度涨超5%
一周IPO丨三只新股齐上涨！健康160、劲方医药双双飙升至翻倍；奇瑞汽车、紫金黄金、西普尼火热招股中
一周财经日历 | 10月再降息25基点？美国8月PCE数据来袭；奇瑞汽车、紫金黄金等3只新股火热招股中
美股消费板块如何布局？瑞银首选清单出炉 百事(PEP.US)、Peloton(PTON.US)在列
电影《大空头》原型研判：美联储本轮降息周期短暂 AI仍是市场重头戏
英伟达与英特尔“世纪联手”引爆芯片产业链! 芯片背后的缔造者们拥抱“看涨狂潮”
新股申购 | 紫金黄金国际、西普尼两只新股今起招股
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
